Shanghai, China, 14 April 2025 – MicroPort EverPace announces that its EasyEcho™ Ultrasound Catheter has been approved for fast-track registration as an innovative medical device by China’s National Medical Product Administration (NMPA). This approval places EasyEcho™ on the NMPA Green Channel, expediting its regulatory review process.
ICE technology represents the cutting edge of cardiac electrophysiology. By placing a miniature ultrasound transducer at the tip of the catheter and delivering it via peripheral vessels (such as veins) into the heart chamber, ICE enables real-time, radiation-free, high-resolution imaging of intracardiac structures and major vessels. This technology significantly reduces radiation exposure, minimizes complications, and shortens both recovery and hospitalization time for patients undergoing cardiac procedures.
EasyEcho™ features 3D ultrasound localization and works in synergy with ultrasound imaging systems and EverPace’s Columbus™ 3D EP Navigation System. This integration enables precise intraoperative visualization, capturing detailed structural and device images alongside accurate 3D positioning to enhance procedural safety and clinical outcomes.
Currently undergoing pre-market clinical trials in China, EasyEcho™ is set to benefit patients
with tachyarrhythmia once approved. Its inclusion in the NMPA Innovation Pathway accelerates regulatory review and expands procedural options for physicians, ultimately improving patient outcomes.
MicroPort EverPace remains committed to driving forward technological innovation in electrophysiology, delivering world-class, integrated interventional solutions that empower both physicians and patients with reliable, high-quality medical care.
About MicroPort EverPace
Founded in 2010, MicroPort EverPace (Shanghai MicroPort EP MedTech Co., Ltd; SSE: 688351), an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853), is a global medical devices company focusing on the development, manufacturing, and commercializing minimally invasive medical devices for the treatment of cardiac arrhythmia. It has developed a family of advanced cardiac ablation catheters, diagnostic catheters, and 3D navigation systems. These solutions are used by hundreds of physicians at over 1000 hospitals over more than 30 countries. MicroPort EverPace strives to provide integrated therapeutic solutions to apply precise navigation on interventional procedures, dedicated to providing high quality therapeutic solutions to patients and physicians across the globe.
More information is available at www.everpace.com/en